COVID-19 诱导的慢性淋巴细胞白血病患者白细胞增多症
COVID-19-Induced Hyperleucocytosis in Chronic Lymphocytic Leukaemia.
作者信息
Singh Balraj, Ayad Sarah, Kaur Parminder, Reid Ro-Jay, Gupta Sachin, Maroules Michael
机构信息
Saint Joseph's University Medical Center, Peterson, NJ, USA.
出版信息
Eur J Case Rep Intern Med. 2021 Mar 15;8(3):002348. doi: 10.12890/2021_002348. eCollection 2021.
UNLABELLED
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for the current global pandemic, coronavirus disease 2019 (COVID-19). COVID-19 usually presents with respiratory symptoms but can affect multiple organ systems. A wide spectrum of complications can occur depending upon the comorbidities of patients. There is limited literature available regarding the presentation and outcome of COVID-19 in chronic lymphocytic leukaemia (CLL) patients. We report 2 cases of COVID-19-induced hyperleucocytosis (WBC count >100,000/μl) in CLL patients.
LEARNING POINTS
Lymphopenia has been associated with severe disease and is a poor prognostic factor in COVID-19 infected patients; however, our cases show COVID-19-induced hyperleucocytosis (WBC count >100,000/μl)/lymphocytosis in CLL patients.Prior reports suggest that ibrutinib may have a protective effect against COVID-19 by decreasing inflammation and preventing progression to ARDS.
未标注
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种新型冠状病毒，引发了当前的全球大流行——2019冠状病毒病（COVID-19）。COVID-19通常表现为呼吸道症状，但可累及多个器官系统。根据患者的合并症情况，可出现广泛的并发症。关于慢性淋巴细胞白血病（CLL）患者中COVID-19的表现和结局的文献有限。我们报告2例CLL患者出现COVID-19诱导的白细胞增多症（白细胞计数>100,000/μl）。
学习要点
淋巴细胞减少与严重疾病相关，是COVID-19感染患者的不良预后因素；然而，我们的病例显示CLL患者出现COVID-19诱导的白细胞增多症（白细胞计数>100,000/μl）/淋巴细胞增多症。先前的报告表明，依鲁替尼可能通过减轻炎症和预防进展为急性呼吸窘迫综合征（ARDS）而对COVID-19具有保护作用。
Zotero 插件